Haemonetics Corporation filed an 8-K press release on November 18, 2026, announcing CE Mark certification for its VASCADE MVP XL venous vascular closure system and reporting that the first commercial European procedures were completed in Germany, Italy, and the United Kingdom.

Key Highlights

  • CE Mark granted: The VASCADE MVP XL venous vascular closure system received CE Mark certification under the EU-MDR, according to the filing.
  • First European procedures: Initial cases were performed in October by physicians at sites in Hamburg, Milan, and London, the filing states.
  • Indicated sheath sizes: The system is CE marked for femoral venous access sites using 10-12F inner diameter (15F maximum outer diameter) procedural sheaths, per the filing.
  • Design differences vs. predecessor: The filing states the VASCADE MVP XL system uses 58% more collagen and a 9% larger disc than the VASCADE MVP system.
  • Targeted procedures: The filing identifies cryoablation, Pulsed Field Ablation, and Left Atrial Appendage Closure as examples of procedures the system is designed to support.
  • Existing portfolio: Haemonetics also holds CE marks under EU-MDR for the VASCADE and VASCADE MVP systems, the filing notes.

Haemonetics Expands VASCADE MVP XL Into European Markets With CE Mark

Haemonetics Corporation (NYSE:HAE) disclosed on November 18, 2026, that its VASCADE MVP XL venous vascular closure system has received CE Mark certification under the European Medical Device Regulation (EU-MDR). According to the filing, the certification enables the company to market the device in the European Union and other geographies that recognize CE marking. The first commercial European procedures using the system were performed in October at three sites: Asklepios Clinic Altona in Hamburg, Germany; Centro Cardiologico Monzino, IRCCS, in Milan, Italy; and Cromwell Hospital in London, UK.

The filing states the VASCADE MVP XL system is CE marked for percutaneous closure of femoral venous access sites, with the stated benefits of reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility compared to conventional closure methods, and enabling same-day discharge in eligible patients. The device is indicated for catheter-based procedures using 10-12F inner diameter (15F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs. The filing attributes to Ken Crowley, Vice President and General Manager, Interventional Technologies at Haemonetics, that the product "has driven the growth of our Interventional Technologies business in the United States."

The filing also describes Haemonetics' broader vascular closure portfolio, noting that the VASCADE system is designed for small-bore femoral arterial and venous closure with standard 5-6/7F procedural sheaths, and the VASCADE MVP system for mid-bore multi-access femoral venous closure with 6-12F ID sheaths. Both are described as CE marked under EU-MDR. The filing includes forward-looking statements regarding commercialization plans and potential product benefits, and notes those statements are subject to risks and uncertainties described in Haemonetics' regulatory filings.

What Was Disclosed

Haemonetics announced CE Mark certification for the VASCADE MVP XL venous vascular closure system under EU-MDR, reported the completion of first commercial European procedures in October 2026, and described the device's indicated uses, design specifications, and position within the company's vascular closure portfolio.